Fan Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fan Yang has a total of 308 co-authors. Here are the top co-authors by number of shared publications:
Jun Wang
Department of Thoracic Surgery, Peking University People’s Hospital, Beijing, China
11 shared publications- Jian Zhou
Department of Thoracic Surgery, Peking University People’s Hospital, Beijing, China
9 shared publications - Jun Wang
Department of Thoracic Surgery, Thoracic Oncology Institute, Peking University People’s Hospital, Beijing, China
9 shared publications - Kezhong Chen
Department of Thoracic Surgery Peking University People's Hospital Beijing China
9 shared publications Yun Li
Department of Thoracic Surgery, Peking University People’s Hospital, Beijing, China
8 shared publicationsGuanchao Jiang
Department of Thoracic Surgery, Peking University People’s Hospital, Beijing, China
7 shared publications
Latest Publications
- 5 January 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (4) , 3226-3227
ASO Author Reflections: Artificial Intelligence-Driven Thoracoscopic Video Analysis for Intraoperative Visceral Pleural Invasion Prediction
- 5 January 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (4) , 3226-3227
ASO Author Reflections: Artificial Intelligence-Driven Thoracoscopic Video Analysis for Intraoperative Visceral Pleural Invasion Prediction
- 22 December 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (4) , 3138-3150
Development and Validation of an Artificial Intelligence Surgical Video Analysis Model for Predicting Visceral Pleural Invasion in Lung Cancer Surgery: A Multicenter Study
Intraoperative diagnosis of visceral pleural invasion (VPI) during video-assisted thoracoscopic surgery (VATS) remains challenging. This study aimed to dev
- 22 December 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (4) , 3138-3150
Development and Validation of an Artificial Intelligence Surgical Video Analysis Model for Predicting Visceral Pleural Invasion in Lung Cancer Surgery: A Multicenter Study
Intraoperative diagnosis of visceral pleural invasion (VPI) during video-assisted thoracoscopic surgery (VATS) remains challenging. This study aimed to dev
- Open Access
- 4 August 2025
- Published by Wiley in Advanced Science
- Vol. 12 (39) , e04498
Unveiling Macrophage Content as a Predictive Biomarker for Intraoperative ICG Imaging Efficacy in Lung Cancer
Due to the phenotypic and genotypic heterogeneity of tumors, the efficacy of intraoperative indocyanine green (ICG) imaging in lung cancer exhibits significant inter‐patient variability. This study identifies macrophage content as a critical predictive biomarker for ICG imaging outcomes, offering both mechanistic, and clinical insights into this variability. Mechanistically, macrophages are demonstrated to serve as the principal ICG reservoirs in tumor tissues, exhibiting seven‐fold higher uptake capacity compared to cancer cells. This critical role is confirmed by significantly diminished ICG accumulation following macrophage depletion in patient‐derived xenograft (PDX) models. Clinically, a strong correlation is observed between imaging quality and macrophage content, with solid nodules exhibiting superior ICG uptake compared to ground‐glass nodules due to higher macrophage infiltration. Furthermore, the strong tumor‐to‐normal ratio (TNR) association with preoperative maximum Standardized Uptake Value (SUVmax) on PET‐CT suggests the feasibility of predicting ICG‐guided surgery outcomes through routine imaging. The substantial contribution of macrophages to this predictive capability is a significant discovery, offering a novel biomarker for patient stratification in ICG‐guided surgery. These insights not only deepen our comprehension of the intricate interplay between ICG and the lung cancer microenvironment but also open new avenues for the development of more personalized and precise surgical strategies.
- 4 August 2025
- Published by Wiley in Advanced Science
- Vol. 12 (39) , e04498
Open AccessUnveiling Macrophage Content as a Predictive Biomarker for Intraoperative ICG Imaging Efficacy in Lung Cancer
Due to the phenotypic and genotypic heterogeneity of tumors, the efficacy of intraoperative indocyanine green (ICG) imaging in lung cancer exhibits significant inter‐patient variability. This study identifies macrophage content as a critical predictive biomarker for ICG imaging outcomes, offering both mechanistic, and clinical insights into this variability. Mechanistically, macrophages are demonstrated to serve as the principal ICG reservoirs in tumor tissues, exhibiting seven‐fold higher uptake capacity compared to cancer cells. This critical role is confirmed by significantly diminished ICG accumulation following macrophage depletion in patient‐derived xenograft (PDX) models. Clinically, a strong correlation is observed between imaging quality and macrophage content, with solid nodules exhibiting superior ICG uptake compared to ground‐glass nodules due to higher macrophage infiltration. Furthermore, the strong tumor‐to‐normal ratio (TNR) association with preoperative maximum Standardized Uptake Value (SUVmax) on PET‐CT suggests the feasibility of predicting ICG‐guided surgery outcomes through routine imaging. The substantial contribution of macrophages to this predictive capability is a significant discovery, offering a novel biomarker for patient stratification in ICG‐guided surgery. These insights not only deepen our comprehension of the intricate interplay between ICG and the lung cancer microenvironment but also open new avenues for the development of more personalized and precise surgical strategies.
- Open Access
- 1 July 2025
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 14 (7) , 2760-2770
Prognostic significance of micropapillary pattern and risk factors in patients with resected stage I lung adenocarcinoma and possible benefit of adjuvant therapy: a real-world multicenter study
Background: Micropapillary (MP) pattern has been identified as a negative prognostic factor in patients with lung adenocarcinoma, but it has not been recognized as a high-risk factor for patients with stage IB lung adenocarcinoma treated with adjuvant chemotherapy. This multicenter cohort study aimed to evaluate the prognostic value of histological subtypes for stage I lung adenocarcinoma and to determine the relative survival benefit of adjuvant chemotherapy for subgroups based on MP pattern. Methods: This retrospective study included 412 patients with stage I lung adenocarcinoma [according the eighth edition of the tumor-node-metastasis (TNM) classification] with MP pattern who underwent complete surgical resection between January 2010 and December 2019. Patients were classified into 3 groups based on the proportion of MP component (10% and 50% as the threshold): MP component >50% (n=8), 10–50% (n=273) and Results: Among the 412 patients, the median age was 63 years, and 73.4% (113/154) patients with MP component ≥10% and 63.8% (51/80) of those with MP component 50% had a shorter overall survival (OS) compared with those with MP components of 10–50% [10–50% vs. >50%: hazard ratio (HR) =0.293, 95% confidence interval (CI): 0.083–1.027; P=0.052] or 2 cm (HR =1.832, 95% CI: 1.138–2.949; P=0.01). Conclusions: MP component and risk factors might be considered critical features for patients with stage I lung adenocarcinomas and may inform the selection of patients who may benefit from adjuvant chemotherapy although no randomized evidence is available.
- 1 July 2025
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 14 (7) , 2760-2770
Open AccessPrognostic significance of micropapillary pattern and risk factors in patients with resected stage I lung adenocarcinoma and possible benefit of adjuvant therapy: a real-world multicenter study
Background: Micropapillary (MP) pattern has been identified as a negative prognostic factor in patients with lung adenocarcinoma, but it has not been recognized as a high-risk factor for patients with stage IB lung adenocarcinoma treated with adjuvant chemotherapy. This multicenter cohort study aimed to evaluate the prognostic value of histological subtypes for stage I lung adenocarcinoma and to determine the relative survival benefit of adjuvant chemotherapy for subgroups based on MP pattern. Methods: This retrospective study included 412 patients with stage I lung adenocarcinoma [according the eighth edition of the tumor-node-metastasis (TNM) classification] with MP pattern who underwent complete surgical resection between January 2010 and December 2019. Patients were classified into 3 groups based on the proportion of MP component (10% and 50% as the threshold): MP component >50% (n=8), 10–50% (n=273) and Results: Among the 412 patients, the median age was 63 years, and 73.4% (113/154) patients with MP component ≥10% and 63.8% (51/80) of those with MP component 50% had a shorter overall survival (OS) compared with those with MP components of 10–50% [10–50% vs. >50%: hazard ratio (HR) =0.293, 95% confidence interval (CI): 0.083–1.027; P=0.052] or 2 cm (HR =1.832, 95% CI: 1.138–2.949; P=0.01). Conclusions: MP component and risk factors might be considered critical features for patients with stage I lung adenocarcinomas and may inform the selection of patients who may benefit from adjuvant chemotherapy although no randomized evidence is available.
- Top Cited Papers
- 12 June 2025
- Published by Elsevier in Cell Stem Cell
- Vol. 32 (8) , 1218-1234.e7
An organoid co-culture model for probing systemic anti-tumor immunity in lung cancer
- 12 June 2025
- Published by Elsevier in Cell Stem Cell
- Vol. 32 (8) , 1218-1234.e7
Top Cited PapersAn organoid co-culture model for probing systemic anti-tumor immunity in lung cancer
- Open Access
- 10 June 2025
- Published by Springer Nature in npj Precision Oncology
- Vol. 9 (1) , 1-4
Case report: a R0 resection successfully induced by T-DXd plus PD-1 inhibitor regimen in a primary unresectable stage IIIB NSCLC with ERBB2-mutation
Chemoradiotherapy (CRT) with consolidative immunotherapy(IO) remains the standard care for unresectable stage III NSCLC, yet survival remains suboptimal in molecular subgroups. Emerging targeted therapies offer the potential for converting unresectable cases to resectable status. We present a 54-year-old female with stage IIIB (T1cN3M0) ERBB2 exon 20-mutated lung adenocarcinoma (PD-L1 50%) and supraclavicular metastasis. After three cycles of ERBB2-targeted antibody-drug conjugate combined with programmed death-1 (PD-1) inhibitor, transient Grade 1 interstitial lung disease resolved with steroids. Serial imaging revealed 58% tumor regression, enabling successful R0 resection via VATS lobectomy with lymphadenectomy. Histopathological analysis confirmed complete pathological response in primary and nodal lesions, corroborated by undetectable postoperative minimal residual disease. The patient remained recurrence-free at a 9-month follow-up. This induction targeted-IO strategy enabled surgical conversion in ERBB2-mutant NSCLC with durable remission and acceptable toxicity, warranting investigation in molecular subgroups with limited CRT-IO benefit.
- 10 June 2025
- Published by Springer Nature in npj Precision Oncology
- Vol. 9 (1) , 1-4
Open AccessCase report: a R0 resection successfully induced by T-DXd plus PD-1 inhibitor regimen in a primary unresectable stage IIIB NSCLC with ERBB2-mutation
Chemoradiotherapy (CRT) with consolidative immunotherapy(IO) remains the standard care for unresectable stage III NSCLC, yet survival remains suboptimal in molecular subgroups. Emerging targeted therapies offer the potential for converting unresectable cases to resectable status. We present a 54-year-old female with stage IIIB (T1cN3M0) ERBB2 exon 20-mutated lung adenocarcinoma (PD-L1 50%) and supraclavicular metastasis. After three cycles of ERBB2-targeted antibody-drug conjugate combined with programmed death-1 (PD-1) inhibitor, transient Grade 1 interstitial lung disease resolved with steroids. Serial imaging revealed 58% tumor regression, enabling successful R0 resection via VATS lobectomy with lymphadenectomy. Histopathological analysis confirmed complete pathological response in primary and nodal lesions, corroborated by undetectable postoperative minimal residual disease. The patient remained recurrence-free at a 9-month follow-up. This induction targeted-IO strategy enabled surgical conversion in ERBB2-mutant NSCLC with durable remission and acceptable toxicity, warranting investigation in molecular subgroups with limited CRT-IO benefit.
- Open Access
- 14 May 2025
- Published by Wiley in Thoracic Cancer
- Vol. 16 (9) , e70073
Prognostic Significance, Radiological, and Metabolic Characteristics of Metastatic Lymph Nodes in Resectable Non‐Small Cell Lung Cancer Following Neoadjuvant Chemoimmunotherapy
Background: Metastatic lymph nodes (mLNs) exhibit different responses to neoadjuvant immunotherapy compared to the primary tumor (PT) in non‐small cell lung cancer (NSCLC). Evaluating mLNs' response is crucial for predicting treatment efficacy and prognosis; however, such assessments are currently insufficient.Methods: We enrolled 101 NSCLC patients with mLNs who underwent neoadjuvant chemoimmunotherapy followed by surgery. Survival outcomes and radiological and metabolic changes were analyzed across different lymph node pathological response groups, and a least absolute shrinkage and selection operator (LASSO) logistic regression model was developed to predict mLNs' response. RNA sequencing was performed to characterize the immune microenvironment of lymph nodes with different pathological responses.Results: Residual tumors in mLNs were significantly associated with worse recurrence‐free survival (p = 0.003) and a trend toward worse overall survival (p = 0.087). Combining the pathological responses of mLNs and PTs improved prognostic stratification. Neither radiological size changes (AUC: 0.621) nor the SUVmax reduction rate (AUC: 0.645) were effective in distinguishing mLNs response. A model combining radiological and metabolic parameters demonstrated fair prediction efficacy (AUC: 0.85). In separate analyses of N1 and N2 nodes, radiological and metabolic changes of N1 mLNs partly reflected their pathologic response (AUC: 0.734; 0.816), unlike in N2 mLNs. RNA sequencing revealed that immune infiltration in responding lymph nodes differed from non‐responding ones, with higher CD8+ T cells, NK T cells, B cells, and dendritic cells in the former.Conclusion: The pathological response of mLNs provides additional prognostic information, but current tools are ineffective for detecting residual tumors. A model integrating radiological and metabolic parameters may offer better prediction.
- 14 May 2025
- Published by Wiley in Thoracic Cancer
- Vol. 16 (9) , e70073
Open AccessPrognostic Significance, Radiological, and Metabolic Characteristics of Metastatic Lymph Nodes in Resectable Non‐Small Cell Lung Cancer Following Neoadjuvant Chemoimmunotherapy
Background: Metastatic lymph nodes (mLNs) exhibit different responses to neoadjuvant immunotherapy compared to the primary tumor (PT) in non‐small cell lung cancer (NSCLC). Evaluating mLNs' response is crucial for predicting treatment efficacy and prognosis; however, such assessments are currently insufficient.Methods: We enrolled 101 NSCLC patients with mLNs who underwent neoadjuvant chemoimmunotherapy followed by surgery. Survival outcomes and radiological and metabolic changes were analyzed across different lymph node pathological response groups, and a least absolute shrinkage and selection operator (LASSO) logistic regression model was developed to predict mLNs' response. RNA sequencing was performed to characterize the immune microenvironment of lymph nodes with different pathological responses.Results: Residual tumors in mLNs were significantly associated with worse recurrence‐free survival (p = 0.003) and a trend toward worse overall survival (p = 0.087). Combining the pathological responses of mLNs and PTs improved prognostic stratification. Neither radiological size changes (AUC: 0.621) nor the SUVmax reduction rate (AUC: 0.645) were effective in distinguishing mLNs response. A model combining radiological and metabolic parameters demonstrated fair prediction efficacy (AUC: 0.85). In separate analyses of N1 and N2 nodes, radiological and metabolic changes of N1 mLNs partly reflected their pathologic response (AUC: 0.734; 0.816), unlike in N2 mLNs. RNA sequencing revealed that immune infiltration in responding lymph nodes differed from non‐responding ones, with higher CD8+ T cells, NK T cells, B cells, and dendritic cells in the former.Conclusion: The pathological response of mLNs provides additional prognostic information, but current tools are ineffective for detecting residual tumors. A model integrating radiological and metabolic parameters may offer better prediction.
- Open Access
- 3 August 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 75, 102769
Development and validation of an integrated system for lung cancer screening and post-screening pulmonary nodules management: a proof-of-concept study (ASCEND-LUNG)
- 3 August 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 75, 102769
Open AccessDevelopment and validation of an integrated system for lung cancer screening and post-screening pulmonary nodules management: a proof-of-concept study (ASCEND-LUNG)
- Open Access
- 1 April 2024
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 13 (4) , 849-860
Efficacy of neoadjuvant chemo-immunotherapy in non-small cell lung cancer: a real-world, multicenter, retrospective study
Background: Resectable non-small cell lung cancer (NSCLC) patients have a high risk of recurrence. Multiple randomized controlled trials (RCTs) have shown that neoadjuvant chemo-immunotherapy brings new hope for these patients. The study aims to evaluate the safety, surgery-related outcomes and oncological outcomes for neoadjuvant chemo-immunotherapy in real-world setting with a large sample size and long-term follow-up. Methods: Patients with clinical stage IB–IIIB NSCLC who received neoadjuvant chemo-immunotherapy at two Chinese institutions were included in this retrospective cohort study. Surgical and oncological outcomes of the enrolled NSCLC patients were collected and analyzed. Results: There were 158 patients identified, of which 124 (78.5%) were at stage IIIA–IIIB and the remaining 34 (21.5%) were at stage IB–IIB. Forty-one patients (25.9%) received two cycles of neoadjuvant treatment, 80 (50.6%) had three cycles, and 37 (23.4%) had four cycles. Twenty-four patients (15.2%) experienced grade 3 or worse immune-related adverse events. The median interval time between the last neoadjuvant therapy and surgery was 37 [interquartile range (IQR), 31–43] days. Fifty-eight out of 96 (60.4%) central NSCLC patients who were expected to undergo complex surgery had the scope or the difficulty of operation reduced. Ninety-five (60.1%) patients achieved major pathologic response (MPR), including 62 (39.2%) patients with pathologic complete response (pCR). Multivariate regression analysis showed that no clinical factor other than programmed death-ligand 1 (PD-L1) expression was predictive of the pathological response. The median follow-up time from diagnosis was 27.1 months. MPR and pCR were significantly associated with improved progression-free survival (PFS) and overall survival (OS). Neither stage nor PD-L1 expression was significantly associated with long-term survival. Conclusions: The neoadjuvant chemo-immunotherapy is a feasible strategy for NSCLC with a favorable rate of pCR/MPR, modified resection and 2-year survival. No clinical factor other than PD-L1 expression was predictive of the pathological response. pCR/MPR may be effective surrogate endpoint for survival in NSCLC patients who received neoadjuvant chemo-immunotherapy.
- 1 April 2024
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 13 (4) , 849-860
Open AccessEfficacy of neoadjuvant chemo-immunotherapy in non-small cell lung cancer: a real-world, multicenter, retrospective study
Background: Resectable non-small cell lung cancer (NSCLC) patients have a high risk of recurrence. Multiple randomized controlled trials (RCTs) have shown that neoadjuvant chemo-immunotherapy brings new hope for these patients. The study aims to evaluate the safety, surgery-related outcomes and oncological outcomes for neoadjuvant chemo-immunotherapy in real-world setting with a large sample size and long-term follow-up. Methods: Patients with clinical stage IB–IIIB NSCLC who received neoadjuvant chemo-immunotherapy at two Chinese institutions were included in this retrospective cohort study. Surgical and oncological outcomes of the enrolled NSCLC patients were collected and analyzed. Results: There were 158 patients identified, of which 124 (78.5%) were at stage IIIA–IIIB and the remaining 34 (21.5%) were at stage IB–IIB. Forty-one patients (25.9%) received two cycles of neoadjuvant treatment, 80 (50.6%) had three cycles, and 37 (23.4%) had four cycles. Twenty-four patients (15.2%) experienced grade 3 or worse immune-related adverse events. The median interval time between the last neoadjuvant therapy and surgery was 37 [interquartile range (IQR), 31–43] days. Fifty-eight out of 96 (60.4%) central NSCLC patients who were expected to undergo complex surgery had the scope or the difficulty of operation reduced. Ninety-five (60.1%) patients achieved major pathologic response (MPR), including 62 (39.2%) patients with pathologic complete response (pCR). Multivariate regression analysis showed that no clinical factor other than programmed death-ligand 1 (PD-L1) expression was predictive of the pathological response. The median follow-up time from diagnosis was 27.1 months. MPR and pCR were significantly associated with improved progression-free survival (PFS) and overall survival (OS). Neither stage nor PD-L1 expression was significantly associated with long-term survival. Conclusions: The neoadjuvant chemo-immunotherapy is a feasible strategy for NSCLC with a favorable rate of pCR/MPR, modified resection and 2-year survival. No clinical factor other than PD-L1 expression was predictive of the pathological response. pCR/MPR may be effective surrogate endpoint for survival in NSCLC patients who received neoadjuvant chemo-immunotherapy.